The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder

Authors
  • A. Heres Diddens
  • S. Kraaijenga
  • V. Coupé
  • F. Hilgers
Publication date 2017
Journal CRANIO
Volume | Issue number 35 | 5
Pages (from-to) 290-297
Organisations
  • Faculty of Dentistry (ACTA)
  • Faculty of Humanities (FGw) - Amsterdam Institute for Humanities Research (AIHR) - Amsterdam Center for Language and Communication (ACLC)
Abstract
Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.

Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.

Results: The point estimate for the incremental cost-effectiveness ratio is −28,068 EUR (−30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.

Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.
Document type Article
Language English
Related dataset The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder
Published at https://doi.org/10.1080/08869634.2016.1232344
Permalink to this page
Back